NCT04179396

Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)

A Phase 1b, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination With Other Anticancer Agents in Patients With Metastatic Castration Resistant Prostate Cancer

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: pharmaand GmbH · Industry
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination with Other Anticancer Agents in Patients with Metastatic Castration Resistant Prostate Cancer

Conditions

• Metastatic Castration Resistant Prostate Cancer

Interventions

Type	Name	Description
DRUG	Rucaparib	Oral rucaparib will be administered twice daily
DRUG	Enzalutamide	Enzalutamide will be administered once daily. Enrollment into Arm A will be prioritized over Arm B until the objectives for Arm A have been achieved.
DRUG	Abiraterone	Abiraterone will be administered once daily with prednisone

Timeline

• Start date: 2019-12-05
• Primary completion: 2021-11-25
• Completion: 2023-01-18
• First posted: 2019-11-27
• Last updated: 2023-06-29
• Results posted: 2023-06-28

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study